🇺🇸 FDA

Intelligence · Drug directory

Pipeline & Investigational Drugs

Investigational and clinical-stage compounds without US or EU marketing approval — linked to ClinicalTrials.gov programs and congress coverage.

Quick answer

Pipeline & investigational drugs: NovaPharmaNews tracks 1,610 pharmaceutical drugs in this segment. Investigational and clinical-stage compounds without US or EU marketing approval — linked to ClinicalTrials.gov programs and congress coverage.

1,610 drugs · Pipeline · by data quality · Page 1 of 68

  1. adenovirus-mediated herpes simplex virus-thymidine kinase gene

    CEREPRO Ark Therapeutics

    EMA: application withdrawn

  2. apomorphine

    APOMINE INTERMITTENT STADA Pharmaceuticals Australia Pty Limited

    EMA: withdrawn · TGA: approved

    G04BE
  3. darvadstrocel

    ALOFISEL Takeda

    EMA: withdrawn

    L04
  4. etirinotecan pegol

    ONZEALD Nektar Therapeutics UK Limited

    EMA: refused

    L01
  5. human igg1 monoclonal antibody specific for human interleukin-1 alpha

    HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH XBiotech Germany GmbH

    EMA: refused

    L01
  6. laquinimod

    NERVENTRA Teva Pharma GmbH

    EMA: refused

    N07
  7. lifileucel

    AMTAGVI Iovance Biotherapeutics B.V.

    EMA: application withdrawn

    L01XL11
  8. mobocertinib

    EXKIVITY Takeda

    EMA: application withdrawn

    L01EB
  9. mozafancogene autotemcel

    FANSKYA Rocket Pharmaceuticals B.V.

    EMA: application withdrawn

  10. peginesatide

    OMONTYS Takeda

    EMA: application withdrawn

    B03XA
  11. plozasiran

    REDEMPLO Arrowhead Pharmaceuticals Ireland Limited

    EMA: unknown

    C10AX
  12. 1-13c-caprylic acid

    GASTROMOTAL

    EMA: application withdrawn

  13. a/vietnam/1194/2004

    AFLUNOV

    EMA: application withdrawn

  14. abetimus

    RIQUENT

    EMA: application withdrawn

  15. abicipar pegol

    RAYOQTA

    EMA: application withdrawn

    S01LA
  16. aducanumab

    ADUHELM

    EMA: application withdrawn

    N07
  17. alendronate sodium trihydrate

    ALENDRONIC ACID / COLECALCIFEROL MYLAN

    EMA: application withdrawn

    M05BB03
  18. alipogene tiparvovec

    GLYBERA

    EMA: unknown

    C10AX10
  19. allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)

    ZALMOXIS

    EMA: withdrawn

    L01
  20. alpha-1-antitrypsin

    INFINIA

    EMA: application withdrawn

    B02AB02
  21. anamorelin

    ADLUMIZ

    EMA: refused

    V03
  22. anecortave acetate

    RETAANE

    EMA: application withdrawn

  23. anti-melanoma mab fragments

    TECNEMAB K1

    EMA: withdrawn

    V09IA02
  24. antithrombin alfa

    ATRYN

    EMA: withdrawn

    B01AB02

Frequently asked questions

How many pipeline drugs are listed?

1,610 drug profiles match this regulatory segment in our published index.

Where does approval data come from?

Profiles combine FDA Drugs@FDA, EMA EPAR references, and regional authority feeds. See our data sources page for attribution.